Market Size in 2023 | Market Forecast in 2032 | CAGR (in %) | Base Year |
---|---|---|---|
USD 56.00 Billion | USD 124.67 Billion | 9.3% | 2023 |
According to Zion Market Research, the global Controlled Release Drug Delivery Market was worth USD 56.00 Billion in 2023. The market is forecast to reach USD 124.67 Billion by 2032, growing at a compound annual growth rate (CAGR) of 9.3% during the forecast period 2024-2032. The report offers a comprehensive analysis of the market, highlighting the factors that will determine growth, potential challenges, and opportunities that could emerge in the Controlled Release Drug Delivery Market industry over the next decade.
Controlled-release drug delivery is a dosage form that delivers medication in a predetermined way. It is a mechanism that facilitates continuous drug delivery in reproducible kinetics for a fixed time throughout the gastrointestinal transit course. It keeps on releasing the drug dosages until it reaches the predetermined region in the gastrointestinal tract. There are several benefits of such a drug delivery system like higher bioavailability, enhanced patient compliance, efficacy, improved drug safety, minimum side effects, lower dose requirement, and improved stability of the drug.
The growing preference of medical professionals for controlled-release drugs coupled with the changing prescription patterns over traditional drug delivery systems is driving the growth of the global controlled-release drug delivery market significantly. Moreover, being a highly fragmented and competitive market, the major market players are proactive with the transforming requirements and are increasingly investing in innovating and developing more advanced drugs to drive the global controlled release drug delivery market vigorously.
The growing research and development activities to develop efficient therapy for non-communicable and chronic diseases like hypertension, diabetes, and cancer are fueling the growth of the market globally. The constantly growing pediatric and geriatric population is boosting the market growth significantly owing to the non-adherence to the medical routine. The geriatric population suffers from biological, mental, and physical malfunction that affects medical intake. Their body is not able to tolerate the optimum dosages and ill effects of drugs and hence it fuels the demand for the controllable release drug delivery system.
The global controlled-release drug delivery market can be segmented into technology, application, release mechanism outlook, and region.
By technology, the market can be segmented into targeted delivery, transdermal, implants, microencapsulation, coacervation, Wurster technique, and others. Targeted delivery accounts for the largest share in the global controlled release drug delivery market due to its added advantages it aids in permitting drugs to stay away from the area or region that might cause drug toxicity and facilities required site of action.
By release mechanism outlook, the market can be segmented into activation-modulated drug delivery systems, micro reservoir partition controlled drug delivery systems, chemically activated, feedback-regulated drug delivery systems, and polymer-based systems. The feedback-regulated drug delivery systems segment dominates the global market due to its high therapeutic efficiency in treating various diseases.
By application, the market can be segmented into drug-eluting stents, infusion pumps, oral controlled-drug delivery systems, injectable, transdermal & ocular patches, and metered dose inhalers. The oral controlled-drug delivery systems hold hegemony over others owing to their frequent uses and wide availability.
Report Attributes | Report Details |
---|---|
Report Name | Controlled Release Drug Delivery Market |
Market Size in 2023 | USD 56.00 Billion |
Market Forecast in 2032 | USD 124.67 Billion |
Growth Rate | CAGR of 9.3% |
Number of Pages | 110 |
Key Companies Covered | APOLLO RT Co. Ltd., Sino Medical-Device Technology Co., Ltd., VIVID IMAGING, GE Healthcare, Nemoto Kyorindo Co., Ltd., Ulrich GmbH & Co. KG, Bayer HealthCare LLC, Medtronic AG, Guerbet Group, Bracco Group, Capsugel, Aradigm Corporation, Pfizer, Inc, Depomed, Inc., Corium International, Inc., Coating Place, Inc., Johnson and Johnson, Alkermes plc, Merck and Co., Inc., F. Hoffman-La-Roche Ltd., Sanofi, Mylan N.V., GlaxoSmithKline plc, Vectura Group plc, Sun Pharmaceuticals Industries Ltd, Abbott Laboratories, Bristol-Myers Squibb Company, and Orbis Biosciences, Inc., among others. |
Segments Covered | By Components, By Deployment, By Organization Size, By Application, By Verticals, And By Region |
Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA) |
Base Year | 2023 |
Historical Year | 2018 to 2022 |
Forecast Year | 2024 - 2032 |
Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
North America accounts for the largest share in the global controlled release drug delivery market owing to the growing supportive initiatives from the government for the developments of the regional market. Moreover, the surging research and development activities are anticipated to propel regional market growth.
Europe is expected to witness huge growth due to the presence of prominent market players in the region coupled with the increasing incidences of patients suffering from chronic illnesses like diabetes, cancer, chronic obstructive pulmonary disease (COPD), and many others.
Asia Pacific is a potential region in the global controlled release drug delivery market and is likely to grow significantly during the forecast period owing to the growing development of healthcare infrastructure and the surging geriatric population in the region.
Some of the major players in the global controlled-release drug delivery market are
By Technology
By Release Mechanism
By Application
By Region
FrequentlyAsked Questions
The global controlled release drug delivery market was valued at USD 56.00 Billion in 2023.
The global controlled release drug delivery market is expected to reach USD 124.67 Billion by 2032, growing at a CAGR of 9.3% between 2024 to 2032.
The growing preference of the medical professionals for the controlled-release drug coupled with the changing prescription patterns over traditional drug delivery systems is driving the growth of the global controlled release drug delivery market significantly. Moreover, being a highly fragmented and competitive market, the major market players are pro-active with the transforming requirements and are increasingly investing in innovating and developing more advanced drugs to drive the global controlled release drug delivery market vigorously.
North America has been leading the Universal Flash Storage Market and is anticipated to continue on the dominant position in the years to come.
Some of the major companies operating in the controlled release drug delivery market are APOLLO RT Co. Ltd., Sino Medical-Device Technology Co., Ltd., VIVID IMAGING, GE Healthcare, Nemoto Kyorindo Co., Ltd., Ulrich GmbH & Co. KG, Bayer HealthCare LLC, Medtronic AG, Guerbet Group, Bracco Group, Capsugel, Aradigm Corporation, Pfizer, Inc, Depomed, Inc., among others.
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed